Diabetic retinopathy

June 23, 2018

Unearthing an unknown function of a known drug: Natural product-based combinatorial therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Telmisartan(angiotensin II receptor antagonist), Epicatechin and Matrine (TEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 23/June/2018, 7.33 am

Unearthing an unknown function of a known drug: Natural product-based combinatorial therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Telmisartan(angiotensin II receptor antagonist), Epicatechin and Matrine (TEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 23/June/2018, 7.33 am https://genomediscovery.org/wp-content/uploads/2018/06/Telmisartan-Epicatechin-and-Matrine-TEM-inhibits-EPHX2-and-attenates-diabetic-retinopathy.jpg2_.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/06/Telmisartan-Epicatechin-and-Matrine-TEM-inhibits-EPHX2-and-attenates-diabetic-retinopathy.jpg2_.jpg June 23, 2018 June 23, 2018

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

June 9, 2018

Combinatorial therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing α-Galactosylceramide, Epicatechin and Matrine (GCEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 9/June/2018, 10.49 pm

Combinatorial therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing α-Galactosylceramide, Epicatechin and Matrine (GCEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 9/June/2018, 10.49 pm https://genomediscovery.org/wp-content/uploads/2018/06/GCEM-inhibits-EPHX2.sEH1-expression-decreases-1920-dihydroxydocosapentaenoic-acid-DHDP-levels-promotes-pericite-viability.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/06/GCEM-inhibits-EPHX2.sEH1-expression-decreases-1920-dihydroxydocosapentaenoic-acid-DHDP-levels-promotes-pericite-viability.jpg June 9, 2018 June 9, 2018

March 29, 2018

Hydrogen gas-based therapy for Diabetic retinopathy: Inhalation of hydrogen gas inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 29/March/2018, 6.43 am

Hydrogen gas-based therapy for Diabetic retinopathy: Inhalation of hydrogen gas inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 29/March/2018, 6.43 am https://genomediscovery.org/wp-content/uploads/2018/03/Hydrogen-gas-attenuates-diabetic-retinopathy.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/03/Hydrogen-gas-attenuates-diabetic-retinopathy.jpg March 29, 2018 March 29, 2018

March 21, 2018

Amino acid-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing L-Serine, Epicatechin and Matrine (SEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 21/March/2018, 1.53 pm

Amino acid-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing L-Serine, Epicatechin and Matrine (SEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 21/March/2018, 1.53 pm https://genomediscovery.org/wp-content/uploads/2018/03/A-1.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/03/A-1.jpg March 21, 2018 March 21, 2018

March 5, 2018

Amino-acid based combinatorial therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Glycine, Epicatechin and Matrine (GEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 5/March/2018, 11.13 am

Amino-acid based combinatorial therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Glycine, Epicatechin and Matrine (GEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 5/March/2018, 11.13 am https://genomediscovery.org/wp-content/uploads/2018/03/A.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/03/A.jpg March 5, 2018 March 5, 2018

February 19, 2018

Combinatorial therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Pantoprazole, Epicatechin and Matrine (PPEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 20/February/2018, 12.28 am

Combinatorial therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Pantoprazole, Epicatechin and Matrine (PPEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 20/February/2018, 12.28 am https://genomediscovery.org/wp-content/uploads/2018/02/A-3.jpg 960 720 Dr Boomi's Genom-2-Discovery Center Dr Boomi's Genom-2-Discovery Center https://genomediscovery.org/wp-content/uploads/2018/02/A-3.jpg February 19, 2018 February 19, 2018

Popular Post